IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Tema ETFs LLC

Tema ETFs LLC boosted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 21.0% during the 2nd quarter, Holdings Channel.com reports. The fund owned 135,847 shares of the company’s stock after purchasing an additional 23,538 shares during the quarter. Tema ETFs LLC’s holdings in IDEAYA Biosciences were worth $5,063,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of IDYA. Handelsbanken Fonder AB grew its stake in shares of IDEAYA Biosciences by 10.7% in the 2nd quarter. Handelsbanken Fonder AB now owns 34,200 shares of the company’s stock worth $1,275,000 after purchasing an additional 3,300 shares during the last quarter. Versant Capital Management Inc lifted its stake in IDEAYA Biosciences by 26.7% during the second quarter. Versant Capital Management Inc now owns 2,825 shares of the company’s stock valued at $105,000 after purchasing an additional 596 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in IDEAYA Biosciences during the first quarter worth approximately $2,875,000. Bank of America Corp DE boosted its holdings in IDEAYA Biosciences by 4.3% during the first quarter. Bank of America Corp DE now owns 942,091 shares of the company’s stock worth $31,390,000 after buying an additional 39,118 shares in the last quarter. Finally, Janus Henderson Group PLC grew its position in IDEAYA Biosciences by 1.1% in the first quarter. Janus Henderson Group PLC now owns 7,265,253 shares of the company’s stock worth $242,023,000 after buying an additional 78,797 shares during the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Royal Bank Of Canada dropped their price target on IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating on the stock in a report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Friday, July 17th. Wall Street Zen upgraded IDEAYA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Wedbush boosted their target price on IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a report on Friday, May 22nd. Fourteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.12.

IDEAYA Biosciences Price Performance

IDYA stock opened at $36.96 on Thursday. IDEAYA Biosciences, Inc. has a 52-week low of $23.23 and a 52-week high of $40.58. The company’s 50 day simple moving average is $34.88 and its 200-day simple moving average is $32.68. The firm has a market capitalization of $3.25 billion, a P/E ratio of -19.05 and a beta of -0.10.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.The firm had revenue of $8.86 million during the quarter, compared to analyst estimates of $8.02 million. During the same period in the prior year, the business posted ($0.88) EPS. The company’s revenue for the quarter was up 8800.0% on a year-over-year basis. Sell-side analysts predict that IDEAYA Biosciences, Inc. will post -4.38 EPS for the current fiscal year.

Insider Activity

In other news, CAO Briseno Andres Ruiz sold 9,550 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total value of $382,095.50. Following the completion of the sale, the chief accounting officer owned 26,466 shares in the company, valued at $1,058,904.66. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.70% of the stock is owned by insiders.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.